Beyond the Scale: Semaglutide Enhances Muscle Strength and Metabolic Health in New Long-Term Study

February 9, 2026

For years, the conversation surrounding the blockbuster weight-loss drug semaglutide (brand names Wegovy and Ozempic) has focused almost exclusively on the “number on the scale.” However, a growing concern among clinicians has been the quality of that weight loss—specifically, whether patients are losing vital muscle alongside fat.

A landmark prospective study published in Diabetes, Obesity and Metabolism provides a reassuring answer. The research, known as the SEMALEAN study, suggests that semaglutide 2.4 mg does more than just suppress appetite; it may actually improve body composition, boost muscle strength, and enhance metabolic efficiency over a 12-month period.

The findings come at a critical time as the medical community shifts its focus from “weight loss” to “metabolic health,” emphasizing the preservation of lean mass to prevent conditions like sarcopenic obesity—a dangerous combination of high body fat and low muscle mass.

Improving the “Quality” of Weight Loss

The SEMALEAN study followed 115 adults with obesity over a one-year period. While the raw weight-loss numbers were impressive—with participants losing an average of 10% of their body weight by month seven and 13% by month twelve—the real story lay in what was being lost.

Using advanced body composition metrics, researchers found that while fat mass decreased substantially, lean mass (which includes muscle) only showed a modest decline in the early stages of treatment before stabilizing.

“The fear with rapid weight loss has always been the ‘frailty trap,'” says Dr. Elena Richardson, a metabolic specialist not involved in the study. “If you lose 20 pounds but 10 of those pounds are muscle, you might end up weaker and with a slower metabolism than when you started. This data suggests semaglutide helps the body selectively target fat while protecting the structural tissues that keep us functional.”

Key Findings at a Glance:

• Weight Loss: 13% average reduction at 12 months.

• Muscle Strength: Handgrip strength increased by an average of 4.5 kg.

• Sarcopenic Obesity: Prevalence dropped from 49% to 33% among participants.

• Metabolic Boost: Resting energy expenditure (adjusted for lean mass) actually increased between months seven and twelve.

The Strength Factor: Reversing Sarcopenia

Perhaps the most surprising result was the improvement in physical function. Traditionally, when people lose significant weight, their absolute strength tends to decrease. However, participants in the SEMALEAN study saw their handgrip strength—a key indicator of overall vitality and longevity—increase by 4.5 kg.

This improvement led to a significant clinical milestone: a 16% reduction in the prevalence of sarcopenic obesity.

“Seeing an increase in grip strength while losing weight is a bit of a ‘holy grail’ in obesity medicine,” notes Dr. Marcus Thorne, a clinical researcher. “It suggests that the weight loss is relieving the metabolic strain on the muscles, allowing them to function more efficiently even if the total volume of lean mass is slightly lower.”

Metabolic Efficiency and the “Plateau” Effect

One of the greatest challenges in weight management is the metabolic slowdown that typically follows weight loss. When the body senses a calorie deficit, it often lowers its Resting Energy Expenditure (REE)—the calories burned at rest—to conserve energy. This is often why patients hit a “plateau.”

The SEMALEAN study found that participants treated with semaglutide actually saw an increase in their REE (when adjusted for lean mass) during the latter half of the year. This suggests that semaglutide may help “retool” the metabolism, making the body more efficient at burning energy even as it grows smaller.

Not All Patients Respond Equally

While the overall results were positive, the study highlighted significant variations in how different groups responded to the medication:

1. Gender Differences: Women generally experienced greater weight and fat loss than men.

2. Pre-existing Conditions: Patients with Type 2 diabetes showed more modest responses compared to those without the condition.

3. Prior Medication Use: Those who had previously used GLP-1 receptor agonists saw smaller incremental gains.

4. Bariatric Surgery: In a notable twist, patients who had previously undergone bariatric surgery and then started semaglutide showed the most significant reductions in body composition measures, suggesting a powerful synergistic effect.

Potential Limitations and Considerations

Despite the promising data, experts urge a balanced interpretation. The study was prospective but included a relatively small sample size of 115 adults. Furthermore, the “stabilization” of lean mass requires long-term monitoring beyond the 12-month mark to ensure the trend continues.

Some critics also point out that “lean mass” as measured by standard scans includes water weight and organ tissue, not just skeletal muscle. While the handgrip strength data provides a functional proxy for muscle health, more granular studies using muscle biopsies or MRI could provide deeper insights.

What This Means for You

For the millions currently using or considering semaglutide, the SEMALEAN study offers a shift in perspective. Weight loss should not be viewed as a race to the lowest number, but as a transition to a more functional body.

Practical Takeaways:

• Prioritize Protein and Resistance Training: While the drug helps preserve muscle, clinicians still recommend a high-protein diet and strength training to maximize these benefits.

• Monitor Function, Not Just Weight: If you are on this medication, pay attention to your energy levels and physical strength. Are you finding it easier to climb stairs or carry groceries? These are better indicators of success than the scale alone.

• Consult Your Physician: Since response varies—especially for those with diabetes or previous surgeries—personalized medical supervision remains essential.

As obesity treatment continues to evolve, the focus is clearly moving toward “quality over quantity.” By proving that fat loss can coexist with muscle gains and metabolic improvements, semaglutide is cementing its role not just as a weight-loss tool, but as a comprehensive metabolic intervention.

Medical Disclaimer

This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

Study Citations:

• Alissou M, Demangeat T, Folope V, et al. Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study. Diabetes Obes Metab. 2026;28(1):112-121. doi:10.1111/dom.70141